Clinical Trials Logo
  1. Home
  2. Advanced Breast Cancer
  3. NCT01311037
  4. Details
NCT01311037 Clinical Trial

The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer

Advanced Breast Cancer Clinical Trial

Official title:
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer A Prospective Trial

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT01311037
Other study ID # RAC# 2081-064
Secondary ID RAC# 2081-064
Status Recruiting
Phase N/A
First received March 6, 2011
Last updated December 11, 2011
Start date January 2009

Study information
Verified date December 2011
Source King Faisal Specialist Hospital & Research Center
Contact Al Sayed, M.D.
Phone +966-1-4423949
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women with Advanced Breast Cancer A Prospective Trial.

Description:

The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women with Advanced Breast Cancer A Prospective Trial.

Recruitment information / eligibility
Status Recruiting
Enrollment 2
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Female
Age group 45 Years to 85 Years
Eligibility Inclusion Criteria:

- Receptor Positive Premenopausal Women with Advanced Breast Cancer.

Exclusion Criteria:

- Any woman other than diagnosis of Receptor Positive Premenopausal with Advanced Breast Cancer.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Other:
• GnRh Analogue and Aromatase Inhibitor
GnRh Analogue and Aromatase Inhibitor

Locations
Country Name City State
Saudi Arabia Kfsh & Rc Riyadh

Sponsors (1)
Lead Sponsor Collaborator
King Faisal Specialist Hospital & Research Center

Country where clinical trial is conducted

Saudi Arabia, 

See also
  Status Clinical Trial Phase
Recruiting NCT04653740 - Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer N/A
Completed NCT02091960 - A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer Phase 2
Recruiting NCT05156619 - Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
Recruiting NCT05173103 - Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Completed NCT00754325 - Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor Phase 2
Recruiting NCT04953377 - PFMT Educational Intervention for Patients With Advancer Breast Cancer N/A
Completed NCT03240224 - Bioinformation Therapy for Breast Cancer Phase 2/Phase 3
Recruiting NCT06193525 - FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test Phase 2
Completed NCT03312738 - A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor Phase 2
Active, not recruiting NCT05063786 - Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) Phase 3
Recruiting NCT05655598 - TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Phase 1
Active, not recruiting NCT02499146 - Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer Phase 1
Completed NCT00445458 - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer Phase 1/Phase 2
Recruiting NCT04456855 - Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Completed NCT04408118 - First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC Phase 2
Recruiting NCT04222413 - Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Phase 1
Completed NCT03205761 - Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer Phase 2
Withdrawn NCT04316169 - Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer Phase 1
Completed NCT00546104 - Phase II Dasatinib Study in Advanced Breast Cancer Phase 2